Abstract
In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation.
MeSH terms
-
Animals
-
Drug Resistance, Neoplasm / drug effects
-
Drug Resistance, Neoplasm / genetics
-
Humans
-
Indoles / pharmacology
-
Indoles / therapeutic use*
-
Melanoma / drug therapy*
-
Melanoma / enzymology
-
Melanoma / genetics
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
-
Proto-Oncogene Proteins B-raf / genetics
-
Proto-Oncogene Proteins B-raf / metabolism
-
Sulfonamides / pharmacology
-
Sulfonamides / therapeutic use*
-
Vemurafenib
Substances
-
Indoles
-
Sulfonamides
-
Vemurafenib
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf